News Headlines
-
Bora Pharmaceuticals Announces Multi-Year Expansion For Midwest Manufacturing Site, As Upsher-Smith Entity Split Is Finalized
8/5/2025
Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) a global leader in pharmaceutical manufacturing, has announced plans for significant investments to expand its manufacturing and packaging capabilities at its facility in Maple Grove, Minnesota.
-
Minaris Advanced Therapies Opens New State-Of-The-Art GMP Facility To Support Global Cell And Gene Therapy Growth
8/4/2025
Minaris Advanced Therapies, a leading global contract development and manufacturing organization and testing provider, has announced the opening of its new GMP manufacturing facility in Munich, Germany.
-
WuXi XDC Achieves GMP Release Of Newly Launched DP3 Facility At Wuxi Site, Scaling Further Drug Product Manufacturing Capacity
8/4/2025
WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the Drug Product 3 ("DP3") facility at the Wuxi site has completed GMP release at the end of July, signifying the company's relentless pursuit of excellence in capacity expansion and business growth.
-
Alveolus Bio Secures Strategic Investment From Shilpa Medicare To Advance Groundbreaking Pulmonary Therapeutics
8/4/2025
Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has announced a strategic financing round led by Shilpa Medicare Limited (BSE: 524742) (NSE: SHILPAMED), a prominent global pharmaceutical company with extensive expertise in respiratory therapeutics manufacturing and biotechnology innovation.
-
Atombeat And BioDuro Announce Strategic Partnership To Launch An AI-Powered Platform For Accelerated Peptide Drug Discovery
8/1/2025
On July 30, 2025, Atombeat Inc., a leading force in AI for drug discovery, and BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO), announced a strategic collaboration to an AI powered platform for accelerated peptide drug discovery.
-
Mallinckrodt, Endo Complete Merger To Create Global, Scaled, Diversified Therapeutics Leader
8/1/2025
Mallinckrodt plc and Endo, Inc. today announced that they have completed their merger to create a global, scaled, diversified therapeutics leader.
-
Repligen Announces Strategic Partnership With Novasign To Further Advance Bioprocessing Digitalization
7/31/2025
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign’s machine learning and modeling workflow into Repligen filtration systems.
-
Charles River And BioTech Social Inc. Pursue Crowdfunding Partnership
7/31/2025
Charles River Laboratories International, Inc. and BioTech Social Inc. (BSI) today announced the exploration of a potential client-centric collaboration to enable Charles River Incubator (CIP) and Accelerator (CAP) Program participants to access the BioTech Funding Portal, an investment crowdfunding platform for life science companies.
-
Psyence BioMed's Strategic Collaboration With PsyLabs Yields Breakthrough In High-Purity Ibogaine Production
7/31/2025
Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract.
-
PL BioScience Announces Major Site Expansion
7/31/2025
PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a significant expansion of company headquarters and future manufacturing capabilities to meet the rapidly growing global demand for safe, animal-free cell culture supplements.